MP80-16 NEUTROPHIL-TO-LYMPHOCYTE RATIO – A SIMPLE BIOMARKER IN TESTICULAR CANCER

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Penis/Testis/Urethra: Benign Disease & Malignant Disease III1 Apr 2017MP80-16 NEUTROPHIL-TO-LYMPHOCYTE RATIO – A SIMPLE BIOMARKER IN TESTICULAR CANCER Ahmet Aydin, Solomon Woldu, Thomas Lowrey, Ryan Hutchinson, Laura-Maria Krabbe, Nirmish Singla, Arthur Sagalowsky, Vitaly Margulis, and Aditya Bagrodia Ahmet AydinAhmet Aydin More articles by this author , Solomon WolduSolomon Woldu More articles by this author , Thomas LowreyThomas Lowrey More articles by this author , Ryan HutchinsonRyan Hutchinson More articles by this author , Laura-Maria KrabbeLaura-Maria Krabbe More articles by this author , Nirmish SinglaNirmish Singla More articles by this author , Arthur SagalowskyArthur Sagalowsky More articles by this author , Vitaly MargulisVitaly Margulis More articles by this author , and Aditya BagrodiaAditya Bagrodia More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2521AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Elevated neutrophil-to-lymphocyte ratio (NLR) has been reported to be a poor prognostic indicator in several malignancies and associated with response to immune checkpoint inhibitors; however the association with testicular cancer has not been evaluated. We explore the association between NLR on staging of testicular germ cell tumors (TGCT). METHODS Retrospective review of institutional testicular tumor database from 2010-2016. Patients with non-TGCT were excluded. Patients were categorized as localized or non-localized based on the presence of retroperitoneal or distant metastasis or elevated serum tumor markers following orchiectomy. Pre-and post-orchiectomy mean serum NLR and was calculated for patients and correlated with disease state. NLR > 4 was assessed separately based on previously reported correlation of this cut-point with prognosis in other malignancies. ROC analysis was used to determine accuracy of the NLR to distinguish patients presenting with clinically non-localized disease. RESULTS 159 pts with TGCT were identified for analysis: seminoma (n=59), NSGCT (n=97), ITGCN (n=2), unknown (n=1). Pre- and post-orchiectomy NLR was available for 61 and 56 patients, respectively. Mean NLR was significantly higher for patients with non-localized TGCT (Table). ROC analysis (Figure) demonstrated that pre-orchiectomy NLR was associated with the presence of non-localized disease (AUC 0.770, p<0.001), while post-orchiectomy NLR trended toward significance (AUC 0.659, p=0.063) as a factor associated with the presence of non-localized disease. Additionally, mean pre-orchiectomy NLR demonstrated a dose-response relationship with IGCCCG risk grouping for metastatic TGCT: good risk - NLR 4.6±4.0, intermediate risk - NLR 5.7±3.4, poor risk - NLR 13.2±9.8, (p=0.013). CONCLUSIONS NLR appears to be predictive of non-localized TGCT. Application of NLR may be useful as a predictive biomarker in a number of settings in which presence or degree of non-localized disease is in question e.g. prior to post-chemotherapy RPLND. Further validation is required. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1087 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Ahmet Aydin More articles by this author Solomon Woldu More articles by this author Thomas Lowrey More articles by this author Ryan Hutchinson More articles by this author Laura-Maria Krabbe More articles by this author Nirmish Singla More articles by this author Arthur Sagalowsky More articles by this author Vitaly Margulis More articles by this author Aditya Bagrodia More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...